KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview

Int J Clin Pharmacol Ther. 2005 Dec;43(12):595-6. doi: 10.5414/cpp43595.
No abstract available

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology*
  • Apoptosis
  • Cell Line, Tumor
  • Clinical Trials, Phase I as Topic
  • Drug Evaluation, Preclinical
  • Humans
  • Indazoles / adverse effects
  • Indazoles / pharmacokinetics
  • Indazoles / pharmacology*
  • Organometallic Compounds
  • Oxidation-Reduction
  • Ruthenium Compounds / adverse effects
  • Ruthenium Compounds / pharmacokinetics
  • Ruthenium Compounds / pharmacology*
  • Transferrin / metabolism

Substances

  • Antineoplastic Agents
  • Indazoles
  • Organometallic Compounds
  • Ruthenium Compounds
  • Transferrin
  • indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III))